08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
09/12/2019 – AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019
25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)
22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program
06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit